This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

NCT00731692 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

970

Enrollment

INDUSTRY

Sponsor class

Stopped The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression

Conditions

Primary Progressive Multiple Sclerosis

Interventions

DRUG: FTY720
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals